Form 8-K - Current report:
SEC Accession No. 0000950170-24-104575
Filing Date
2024-09-09
Accepted
2024-09-09 09:02:20
Documents
12
Period of Report
2024-09-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-20240909.htm   iXBRL 8-K 48866
2 EX-99.1 prld-ex99_1.htm EX-99.1 25986
  Complete submission text file 0000950170-24-104575.txt   226910

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240909.xsd EX-101.SCH 50256
14 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240909_htm.xml XML 4721
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 241286028
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)